KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Total Debt (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of Total Debt data on record, last reported at $2.6 billion in Q4 2025.

  • For Q4 2025, Total Debt rose 13.71% year-over-year to $2.6 billion; the TTM value through Dec 2025 reached $2.6 billion, up 13.71%, while the annual FY2025 figure was $2.6 billion, 13.71% up from the prior year.
  • Total Debt reached $2.6 billion in Q4 2025 per AMRX's latest filing, roughly flat from $2.6 billion in the prior quarter.
  • Across five years, Total Debt topped out at $2.7 billion in Q1 2021 and bottomed at $54.4 million in Q1 2022.
  • Average Total Debt over 5 years is $2.1 billion, with a median of $2.5 billion recorded in 2024.
  • Peak YoY movement for Total Debt: soared 5813.4% in 2021, then crashed 98.02% in 2022.
  • A 5-year view of Total Debt shows it stood at $2.7 billion in 2021, then decreased by 3.88% to $2.6 billion in 2022, then dropped by 7.7% to $2.4 billion in 2023, then dropped by 6.54% to $2.3 billion in 2024, then grew by 13.71% to $2.6 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Total Debt were $2.6 billion in Q4 2025, $2.6 billion in Q3 2025, and $2.4 billion in Q2 2025.